This makes mantle cell lymphoma quite rare. Mantle cell lymphoma is about three times more common in men than in women, and mostly affects people over the age of 60.

The early days of mantle cell lymphoma were in the 1980s, said Timothy Fenske, a physician and professor at the Medical College of Wisconsin who presented the study at the annual American Society ...

WASHINGTON - The U.S. Food and Drug Administration has granted approval to AstraZeneca (NASDAQ:AZN)'s Calquence (acalabrutinib), in combination with bendamustine and rituximab, for the treatment ...

December 19, 2007 (Atlanta) — Results obtained with an intensive immunotherapy regimen in mantle-cell lymphoma are so good that they suggest that a cure is in sight, said Christian Geisler, MD ...

Mantle cell lymphoma (MCL) remains one of the more challenging B-cell non-Hodgkin lymphomas, distinguished by its aggressive clinical course and complex molecular signature. Recent investigations ...

Panelists discuss how emerging Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine ...

Feb. 5. 2025 – The FDA has approved a new pill to treat adults with a type of blood cancer called mantle cell lymphoma (MCL). This treatment is for people who are newly diagnosed or haven't had ...

Recent research has suggested auto-HSCT may not improve survival. “The typical patient with mantle cell lymphoma is in their mid- to late 60s, often with medical comorbidities,” Fenske said.

Dr Kumar is an expert in lymphoma and mantle cell lymphoma at Memorial Sloan Kettering. Anita, welcome to InDiscussion. Anita Kumar, MD: Thank you so much, Peter, for having me.

Session ID: 2025-07-24:8ba6782843bac7baf571d8e Player Element ID: V3158cc4a_97bd_4678_b706_c9db5888db1f_6368717568112 ...

Like many cancers, mantle cell lymphoma can vary in how quickly it develops and its severity. As Szubanski's cancer has been described as "fast-moving" and is already stage 4, it appears that it ...